Newly signed DA in 2025 Forma-I (radiofrequency, RF): Heats the eyelids/periorbital tissue to melt meibum and improve gland expression; Health Canada has certified Forma-I for DED due to MGD symptoms in the periorbital/eyelid area. Lumecca-I (intense pulsed light, IPL): Targets periocular inflammation and abnormal vasculature, supporting MGD management (FDA-cleared for pigment/vascular indications around the eyes; widely used in eye-care pathways for DED). IPL ± RF: Reviews and clinical studies report improved TBUT, symptoms, and gland metrics in MGD when IPL is added; combination RF+IPL can further enhance outcomes